Laprosep (Latanoprost)

Latanoprost binds to FP receptors in the eye’s ciliary muscle, increasing uveoscleral outflow of aqueous humor. This enhanced drainage reduces intraocular pressure, which is the primary therapeutic goal in glaucoma management.

The dosing regimen for Laprosep is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and schedule must follow the clinician’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Laprosep.

To request Laprosep, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost is often preferred for its once‑daily dosing and strong intraocular pressure‑lowering effect. Compared with beta‑blocker eye drops, it typically offers greater pressure reduction with a different side‑effect profile, such as cosmetic changes to eyelashes and iris colour.

Laprosep should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discoloured or contaminated.

Laprosep is applied as an ophthalmic solution. The patient places one drop into the conjunctival sac of the prescribed eye(s) once daily, usually in the evening, taking care not to touch the tip of the bottle to the eye or surrounding tissues.

Serious adverse events, though rare, include a paradoxical increase in intraocular pressure, uveitis, macular edema, and severe allergic reactions. Any sudden vision changes, eye pain, or swelling should prompt immediate medical evaluation.

Patients with active ocular inflammation, known hypersensitivity to latanoprost or any component of the formulation, and those for whom prostaglandin analogues are contraindicated should avoid using Laprosep. A healthcare professional should assess suitability before prescribing.